HeartBeam Inc. (NASDAQ: BEAT) reported second-quarter 2026 financial and operational results, showcasing significant advancements in its heart attack detection program and a strengthened cash position. The company, which is developing a cable-free 3D ECG device, announced that it has extended its cash runway into 2027, providing it with the resources to continue its clinical trials and initial commercial rollout.
One of the key highlights from the quarter is the completion of enrollment in its ALIGN-ACS pilot study, which enrolled 134 patients ahead of schedule. The full results are expected to be presented at TCT 2026, a major cardiology conference. Additionally, the company has surpassed 50% enrollment in its larger HEADSTART-ACS pilot study, which aims to enroll 500 patients. These studies are critical for validating the efficacy of HeartBeam’s technology in detecting heart attacks, a leading cause of death worldwide.
HeartBeam also reported progress in its product development, having completed a working prototype of its 12-lead ECG extended wear patch. This patch is designed to be worn by patients for extended periods, allowing for continuous monitoring of cardiac activity. The company has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, marking the beginning of its commercial presence.
Financially, HeartBeam reported a net loss of $5 million for the second quarter, or $0.10 per share, consistent with the prior year’s loss on a dollar basis but improved on a per-share basis due to a higher share count. The company ended the quarter with $8.8 million in cash, cash equivalents, and restricted cash. Management expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, is expected to fund operations into 2027.
The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software was cleared in December 2025. This software enables the synthesis of a standard 12-lead ECG from signals collected by the device, which is designed to be used by patients outside of medical facilities. HeartBeam holds over 20 issued patents related to its technology, positioning it as a potential leader in portable cardiac monitoring.
The implications of these developments are significant. If the pilot studies yield positive results, HeartBeam’s technology could provide a breakthrough in the early detection of heart attacks, potentially saving lives by enabling timely intervention. The company’s progress in commercial agreements and initial shipments indicates that it is moving from development to commercialization, a critical step for any medical technology company.
Investors and healthcare professionals will be watching closely for the ALIGN-ACS results at TCT 2026, as they will provide key data on the device’s accuracy and reliability. With its extended cash runway, HeartBeam appears well-positioned to navigate the regulatory and market challenges ahead.
